Form 4: Clover Health Director Buys Shares

Clover Health Director Anna U. Loengard acquired 26,500 shares of Class A Common Stock through family IRAs, while also reporting a reduction in beneficial interest due to an ex-spouse's holdings.

Summary

• Director Anna U. Loengard purchased 26,500 shares of Clover Health Class A Common Stock on August 13, 2025.
• The purchases were made through custodial IRAs for her son (12,000 shares at $2.60 per share) and daughter (14,500 shares at $2.59 per share).
• Following these transactions, indirect beneficial ownership includes 27,600 shares in the son's IRA and 29,610 shares in the daughter's IRA.
• Direct beneficial ownership stands at 448,091 shares.
• The filing also notes that 151,725 shares previously reported as beneficially owned by the director, held by her ex-spouse, are no longer reportable.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The director's purchase of shares is a positive signal, indicating confidence. However, the amount purchased is relatively small compared to existing holdings, and the reduction in reported beneficial interest due to an ex-spouse's holdings is a neutral event, preventing a higher score.

Positives

• A director, Anna U. Loengard, purchased 26,500 shares of Class A Common Stock, indicating confidence in the company's future.
• The purchases were made at prices of $2.60 and $2.59 per share.

Negatives

• The beneficial interest in 151,725 shares previously held by the director's ex-spouse is no longer reportable, representing a significant reduction in the total reported beneficial ownership.

Future Outlook

NA

Industry Context

Insider buying by a director in a healthcare technology company like Clover Health (which focuses on Medicare Advantage) can signal internal confidence in the company's strategy and market position, especially within the competitive and evolving healthcare sector.

Comparison to Industry Standards

• Insider purchases, especially by directors, are generally viewed positively as they align management's interests with shareholders.
• The reported purchase of 26,500 shares is a modest amount compared to the director's existing direct holdings of 448,091 shares, but still represents a direct investment.
• The reduction in reported beneficial interest due to an ex-spouse's holdings is a personal matter and not indicative of company performance or a sale by the director.

Related Party Transactions

• Director Anna U. Loengard acquired shares indirectly through custodial IRAs for her son and daughter, for which she serves as custodian.

Stakeholder Impact

• Shareholders: May view the director's share purchases as a positive sign of management confidence, potentially bolstering investor sentiment.

Key Dates

Recommendation

While the director's purchase of shares is a positive indicator of internal confidence, the relatively modest size of the purchase compared to existing holdings, combined with the neutral impact of the beneficial interest reduction due to personal circumstances, suggests a "hold" recommendation. It's a positive signal, but not strong enough to warrant a "buy" without further fundamental analysis.

Keywords

Clover Health, CLOV, Insider Buying, Form 4, Director Share Purchase, Anna U. Loengard, SEC Filing, Healthcare Technology, Medicare Advantage